Stock Screener App

Gratuito - Play StoreApp Store

Installare Installare

Dow:

Nasdaq:

S&P 500:

NVS

$160.790.19%-0.31

Dopo l'orario di chiusura: 161.10+0.31 +0.19%

Novartis Ag Adr (NVS)

Date: O: H: L: C: Vol:

Novartis Ag Adr Borsa (NVS) Ultime notizie

Novartis AG (NVS) Seasonal returns chart - Yahoo Finance UK

Novartis AG (NVS) Stock Up 3.2% but GF Value Says Overvalued -- GF Score: 79/100 - GuruFocus

China Upends Global Drug Development With Cheap and Rapid Human Trials - Bloomberg.com

INCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View Raised - Zacks Investment Research

Should You Buy Royalty Pharma Stock Before Nov. 4? - The Motley Fool

Novartis AG (NVS) Stock Forecasts - Yahoo! Finance Canada

Novartis AG : Bernstein reiterates its Neutral rating - www.marketscreener.com

Novartis AG : JP Morgan reiterates its Buy rating - marketscreener.com

Novartis AG Stock 12‑Month Price Target Raised to $158.2, Implies 1% Upside - TradingView

Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight - GlobeNewswire Inc.

How Are LLY's Neuroscience and Immunology Drugs Poised Ahead of Q3? - Zacks Investment Research

The Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVie - Zacks Investment Research

Novartis AG (NVS) Stock Forecasts - Yahoo Finance

What Novartis (NVS) Said on Its Q3 Earnings Call - Yahoo Finance

Novartis AG (NVS) (Q3 2026) Earnings Call Highlights: Raised Gui - GuruFocus

Novartis AG (NVS) (Q3 2026) Earnings Call Highlights: Raised Guidance and Priority Brand ... - Yahoo Finance

Novartis Says 'Well on Track' for Long-Term Outlook Despite $1.9B Avidity Hit - Novartis (NYSE:NVS) - Benzinga

4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential - Zacks Investment Research

NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss - Zacks Investment Research

Novartis takes $1.9bn writedown on key drug after blockbuster Avidity acquisition - Financial Times

NOVARTIS AG N (NOTA.DU) Q3 FY2026 earnings call transcript - Yahoo Finance

The Zacks Analyst Blog Highlights Intel, Novartis AG, Itau Unibanco and AMREP - Yahoo Finance

Novartis Raises Outlook on Growth of New Medicines - Bloomberg.com

Novartis lifts profit outlook as new medicines counter generic erosion (NVS:NYSE) - Seeking Alpha

Novartis reports Q3 core EPS $2.46 vs. $2.25 last year - TipRanks

Novartis AG reports results for the quarter ended September 30 - Earnings Summary - TradingView

Novartis Q3 Core Earnings, Net Sales Increase; 2026 Net Sales Growth Outlook Maintained - Yahoo Finance

Novartis: Q3 Earnings Snapshot - Yahoo Finance

Top Analyst Reports for Intel, Novartis & Itau Unibanco - Zacks Investment Research

Earnings To Watch: Novartis AG (XSWX:NOVN) Q3 2026 -- GF Value Sees 8% Downside - Yahoo Finance

Novartis AG : UBS sticks Neutral - marketscreener.com

Novartis MS Pill Trials Trigger Analyst Skepticism on Peak Sales - Bloomberg.com

Novartis AG : Gets a Neutral rating from RBC - marketscreener.com

Novartis AG : Gets a Neutral rating from Barclays - marketscreener.com

Novartis: Strong Drug Growth Faces A Tougher Test As Patent Losses And Pipeline Setbacks Mount - Seeking Alpha

Novartis Reports Positive Results from Late-stage Studies for Remibrutinib - marketscreener.com

Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity - Yahoo Finance

Novartis AG (NVS) Discusses REMODEL Trial Results for Remibrutinib in Relapsing Multiple Sclerosis - Slideshow - Seeking Alpha

Novartis AG Remibrutinib in MS Investor Call Transcript - GuruFocus

Novartis AG (NVS) Stock Down 3.3% but Still Overvalued -- GF Score: 75/100 - GuruFocus

Novartis AG : RBC is Neutral - marketscreener.com

Novartis Multiple Sclerosis Pill Missed Expectations in Key Study - Bloomberg.com

Novartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib - Reuters

Novartis’ Kisqali Cuts Death Risk 19% in Breast Cancer Study - Bloomberg.com

Novartis AG Stock (NVS) Moved Down by 3.61% on Oct 23: Facts Behind the Movement - TradingKey

Novartis AG Estimates – BX:NOT - TradingView

Novartis AG expected to post earnings of $2.29 a share - Earnings Preview - TradingView

AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA Nephropathy - Zacks Investment Research

Novartis AG Lobbying Profile, 2004 - OpenSecrets

Earnings Preview: Novartis AG to Report Financial Results on October 27 - Moomoo

Simile a NVS

AZN$186.657.02%

AMGN$466.011.15%

MRK$149.522.18%

GILD$170.683.06%